Cited by

• Emerging role of multikinase inhibitors for refractory thyroid cancer.

  Perez CA, Arango BA, Velez M, Raez LE, Santos ES. Perez CA, et al. Biologics. 2012;6:257-65. doi: 10.2147/BTT.S24465. Epub 2012 Aug 8. Biologics. 2012. PMID: 22904617 Free PMC article.
• Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.

  Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H. Kersting C, et al. J Clin Pathol. 2006 Jun;59(6):585-90. doi: 10.1136/jcp.2005.028373. Epub 2006 Feb 3. J Clin Pathol. 2006. PMID: 16461571 Free PMC article.
• Personalization of targeted therapy in advanced thyroid cancer.

  Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A. Fallahi P, et al. Curr Genomics. 2014 Jun;15(3):190-202. doi: 10.2174/1389202915999140404101902. Curr Genomics. 2014. PMID: 24955027 Free PMC article.
• Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase.

  Aghajan M, Jonai N, Flick K, Fu F, Luo M, Cai X, Ouni I, Pierce N, Tang X, Lomenick B, Damoiseaux R, Hao R, Del Moral PM, Verma R, Li Y, Li C, Houk KN, Jung ME, Zheng N, Huang L, Deshaies RJ, Kaiser P, Huang J. Aghajan M, et al. Nat Biotechnol. 2010 Jul;28(7):738-42. doi: 10.1038/nbt.1645. Epub 2010 Jun 27. Nat Biotechnol. 2010. PMID: 20581845 Free PMC article.
• Genetic predictors of MEK dependence in non-small cell lung cancer.

  Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB. Pratilas CA, et al. Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223. Cancer Res. 2008. PMID: 19010912 Free PMC article.